Genetic manipulation of the vasculature may offer insights into the pathogenesis of coronary artery disease and may lead to gene therapy for disorders such as restenosis after percutaneous coronary angioplasty. The goal of this study was to develop a percutaneous method for gene transfer into coronary arteries of intact animals. Liposomes were used to facilitate transfection in coronary arteries with a plasmid containing the cDNA encoding luciferase. This reporter was chosen since it is not expressed in mammalian cells, and it can be quantified using a sensitive assay (light production). Mongrel dogs were catheterized, and DNA was delivered to coronary arteries via a porous perfusion balloon system. Luciferase expression was measured 3-5 days after the procedure, when the dogs were killed. Luciferase activity in control arteries (n = 12) was no higher than average background activity. Eight of 12 transfected arteries exhibited gene expression, averaging 4.3+±2.1 pg luciferase (p<O.Ol, transfected versus control arteries). In addition, the ability to transfect DNA into femoral arteries without a transfection vehicle was tested. Five dogs were subjected to surgical transfection attempts in their femoral arteries with either DNA alone or DNA plus liposomes. Luciferase was expressed in all 10 femoral arteries; those treated with DNA alone expressed 35.6±8 pg luciferase, and those treated with DNA plus liposomes expressed 42.3+14 pg luciferase (p =0.70). These results demonstrate the use of a percutaneous catheter to achieve gene transfer and expression in coronary arteries of intact dogs and suggest that the efficiency of intra-arterial gene transfer may be similar whether or not a transfection vehicle is used. (Circulation Research 1992;71:27-33) 
P ercutaneous transluminal coronary angioplasty (PTCA) is widely used for the treatment of human coronary artery disease, with over 300,000 procedures performed in the United States in 1990. 1 The major limitation of PTCA is restenosis of the vascular lesion, and recent studies describe restenosis rates ranging from 30% to 40% within 6 months of the procedure. 23 Mechanical approaches with atherectomy devices, stents, or specialized balloon catheters have not, to date, significantly reduced the restenosis rate. 4 Systemic drug therapy has yet to be effective. [5] [6] [7] Animal studies suggest that localized delivery of therapeutic agents, in concentrations not tolerated systemically, may reduce restenosis.8 9 Intracoronary site-specific gene transfer may allow production of therapeutic proteins in concentrations sufficient to combat restenosis. 10 Thus, gene therapy for the treatment of human disorders such as post-PTCA restenosis has a potential application.1'
Reports from several investigators suggest that gene transfer may be accomplished in the vasculature.12 retroviruses could introduce reporter genes into endothelial cells in vitro. The genetically altered cells were reintroduced into vascular segments of intact animals and continued to express marker protein (,B-galactosidase) for at least 5 weeks. In an in vitro study, Dichek et al15 proved that a physiologically active protein could be produced by transfecting sheep endothelial cells seeded onto metallic stents with cDNA encoding for tissue plasminogen activator. Production of tissue plasminogen activator significantly surpassed that of nontransfected cells. Nabel Figure 3 and "Results"), and no precipitates were observed with the use of this ratio. In the initial seven animals (nine treated arteries), 4 The distal catheter was then occluded, and the lumen was filled with 1 ml transfection solution. The proximal catheter was then occluded with intra-arterial pressure maintained at 0.5-1.0 atm. The transfection solution was allowed to incubate in the isolated vascular segment. After 1 hour, the lumen was flushed with lactated Ringer's solution, the ligatures were removed, and normal blood flow was reestablished. The incision over the femoral artery was repaired. One gram of nafcillin was given intramuscularly. The animal was allowed to recover from anesthesia and extubated. The transfected femoral arterial segment and sections of the nontransfected femoral artery were taken at the time of harvesting of the coronary segments in each animal. The femoral segments were also placed in coded containers containing PBS and stored at 4°C until assay for luciferase activity. Testing for Gene Expression Using DNA Alone Versus DNA Plus Liposomes Transfection efficiency using DNA alone was compared with DNA plus liposomes in an additional five animals. The surgical technique described above was used; right and left femoral arteries were isolated in each animal, and transfection segments were created. The transfection solution of plasmid DNA alone was infused into one femoral artery; plasmid DNA plus liposomes were infused into the other femoral artery.
The concentration of DNA was 30 ,u.g/ml (90 ugg total) for each preparation. For the solution containing DNA total volume of infusion was increased to an average of plus liposomes, the liposome concentration was 30 ,ug/ml. The incubation time for each segment was 1 hour. Animals were killed 2-3 days after the procedure, and luciferase activity was analyzed. Each arterial segment was placed in a coded container to allow blinded analysis as described above.
Data Analysis
Analysis by the Wilcoxon signed-rank test was applied to the luciferase activity in the coronary transfected arteries and their controls.24 Values are expressed as mean+±SEM.
Results

Coronary Artery Transfection With Percutaneous Balloon Catheter
The results for coronary transfection with the percutaneous catheter are shown in Figure 2 . Of the 17 transfection attempts in 15 animals, two arteries were precluded from analysis because of animal death (one animal had ventricular fibrillation before DNA could be infused; the other died within 8 hours of the procedure after dissection of the LAD was seen during the catheterization). In one animal, the balloon could not be advanced to the target vessel. Two animals were excluded because of precipitates (see "Materials and Methods") in the transfection solution. Thus, 12 transfected arteries and controls from 10 animals were available for analysis.
The luciferase activity for the 12 paired control arteries was 0.3+0.1 pg (no difference from average background activity of 0.4 pg). The luciferase activity for arterial segments (n=7) downstream from the treated segment also was no different from background activity (0.26+0.1 pg). After subtraction of background light unit activity from each treated sample, eight of the 12 transfected arteries demonstrated luciferase activity above the control value (Figure 2 ). The average luciferase activity for these 12 arteries was 4.3+±2.1 pg. When compared with the activity in the 12 paired control arteries, this difference was statistically significant (p=0.009).
Durations of DNA infusion for each artery and resultant luciferase expression are given in Table 1 . The initial seven arteries were transfected for an average of 1.5+±0.2 minutes, and six of these demonstrated gene expression. The subsequent five arteries were transfected for 9.8±+0.9 minutes, and two of these had significant luciferase activity. For the eight arteries demonstrating gene expression, total luciferase activity appeared to be augmented with longer durations of DNA infusion.
Three of the 12 arteries were transfected at an infusion pressure of 2 atm (arteries 8, 10, and 12). The Transfection in Femoral Arteries With Surgical Method Eight of the 10 animals undergoing coronary transfection with the percutaneous balloon catheter technique also had transfection procedures in the femoral artery with the surgical method (the two animals transfected in both the LAD and LCX did not have surgical controls). The transfection success rate was 100% in these eight arteries, with an average luciferase activity above the control value of 27.5+±9.9 pg.
In Vitro Studies for Determination of Optimal DNAILiposome Ratio
The results for the in vitro studies done in response to precipitates occurring in the transfection solution during the course of the study are shown in Figure 3 . As demonstrated, when DNA concentration was kept constant and the liposome concentration was varied, at a 1:1 (wt/wt) ratio the relative luciferase activity was greater than twice that obtained at a ratio of 1: 3. Thus, concentrations of 30 ,g DNA and 30 ,ug liposomes per milliliter OptiMem were used in the transfection solution for the subsequent in vivo experiments.
Intra-arterial Transfection Efficacy for DNA Alone Versus DNA Plus Liposomes in Femoral Arteries Using Surgical Technique Table 2 gives the luciferase activity for each of the five animals that had transfection attempts in both femoral arteries using the surgical method. DNA alone was infused in one femoral artery, and DNA plus liposomes were infused in the other femoral artery. Control arterial segments from each animal did not have luciferase activity above background activity. In the 10 treated arteries, transfection success was 100%. No difference in luciferase production was seen between the two groups, with arteries transfected with DNA plus liposomes averaging 42.3±13.4 pg and those transfected with DNA alone averaging 35.6±7.6 pg (p=0.70). The present study reports intracoronary gene transfer using an interventional technique. The use of a porous balloon catheter with perfusion capabilities allowed blood flow to the distal coronary artery during the delivery of DNA. Other innovative uses of the percutaneous catheter may prove equally effective or superior to this method for intracoronary gene transfer. In addition, the use of stents made of bioabsorbable polymers29,30 for DNA delivery would combine site-specific delivery of the gene of interest with extended duration of exposure of the arterial cells to the gene, and this method is currently being investigated in our laboratory.
Further issues to be resolved from this study include optimizing parameters that will enhance the level of gene product obtained with the percutaneous catheter technique. This may entail use of different enhancers/ promoters for the cDNA construct, improved use of the current device, longer incubation times for the transfection solution, use of higher infusion pressures, or different means of DNA delivery to the arterial site. The use of DNA alone for intracoronary gene transfer with a percutaneous device will be tested, and this may obviate a limitation of this study, namely the interaction of liposomes with the plasmid DNA and the effect of proper liposome concentration on in vivo gene transfer.
Another limitation is the current lack of immunolocalization technology to identify which cells are being transfected with the luciferase construct.'7 We hypothesize that all cell types of the arterial wall are being transfected, given the findings from other investigators16 using the CMV promoter applied in the present study. The present study demonstrated gene expression 3-5 days after introduction of DNA to the arterial segment. This brief period of expression may be sufficient to modify processes such as restenosis after PTCA, given that the stimulus for cellular proliferation seen in this disorder appears to occur immediately after angioplasty, and early intervention at the molecular level may inhibit restenosis. 31 In summary, results from this study demonstrate that a percutaneous balloon catheter may be used to effect gene transfer and expression in the coronary arteries of intact animals. In addition, intra-arterial gene transfer with DNA alone may be just as effective as gene transfer using a transfection vehicle such as liposomes. It is hypothesized that a percutaneous interventional approach to gene therapy in human disorders such as post-PTCA restenosis has a potential application.
